Rakesh Jhunjhunwala cuts its stake in Lupine; stock remains under pressure, loses more than 4% so far this year


Previously, Rakesh Jhunjhunwala held 1.6% of the capital or 72.45 lakh shares of Lupine

Rakesh Jhunjhunwala reduced his stake in pharmaceutical major Lupine to less than 1%. Previously, Rakesh Jhunjhunwala held a 1.6 percent or 72.45 lakh stake in Lupine, as of June 30, 2021. However, Rakesh Jhunjhunwala’s name did not appear in the list released by the company earlier this week according to the last shareholding file. Companies do not need to report the names of shareholders who hold less than one percent of the company’s capital. Trendlyne shows that Rakesh Jhunjhunwala’s stake in Lupine is “less than 1%” as of September 30, 2021.

Also read: Rakesh Jhunjhunwala share: Tata Motors share price increases 20% thanks to TPG investment in electric vehicle sector; can increase by 20% more

See also  Nifty, Bank Nifty consolidates but the overall structure remains positive; watch out for these actions

Lupine share performance

Lupine’s share price fell more than half a percent to Rs 958 each on BSE, even as BSE Sensex jumped 0.7%, hitting a new high. The stock has fallen by half a percent in the past five days and down 2.4 percent in the last month. While, since the start of the year (YTD), Lupine shares have lost 4.14% and 8.6% in six months. Analysts say the pharmaceutical sector as a whole is on a positive note, but Lupin’s low ROE has not benefited investors at all.

The operational performance of the company also remained weaker. “However, the outlook for Lupine appears stable given the continued healthy growth of India’s pharmaceutical sector and the gradual increase in sales in the United States which could improve its margins. Investors may hold the stock for the purpose of 980 in the medium term, ”Ravi Singh, vice president – head of research, Share India Securities, told The US Express News Online.

See also  Stock markets in turmoil as US Federal Reserve begins tapering talks; large caps, preferred PSUs

Despite a rally in the Indian stock market as a whole, Lupine shares reigned under pressure. Analysts said the exit of the leading investor with little interest in defensive sectors like pharmaceuticals led Lupine stock to remain under pressure despite a strong overall bull market. “Technically, Rs 980 remains strong resistance and until there is no close above this level, Rs 920-930 could be reached in the next few sessions,” said AR Ramachandran, co-founder and trainer, Tips2Trades, at The US Express News Online.

(The stock recommendations in this story are by the respective research analysts and brokerage firms. The US Express News Online assumes no responsibility for their investment advice. Investments in the capital markets are subject to rules and regulations Please consult your investment advisor before investing.)

Get live stock quotes for BSE, NSE, US market and latest net asset value, mutual fund portfolio, see the latest IPO news, top IPOs, calculate your tax with the help of the income tax calculator, know the best winners, the best losers and the best equity funds in the market. Like us on Facebook and follow us on Twitter.

See also  SBI, Titan, Sun Pharma among 286 stocks to hit 52-week BSE highs even as Sensex, Nifty drop

The US Express News is now on Telegram. Click here to join our channel and stay up to date with the latest news and updates from Biz.



Please enter your comment!
Please enter your name here